Przejdź do zawartości
Merck
  • Transcutaneous aortic valve replacement with the Edwards SAPIEN XT and Medtronic CoreValve prosthesis under fluoroscopic guidance and local anaesthesia only.

Transcutaneous aortic valve replacement with the Edwards SAPIEN XT and Medtronic CoreValve prosthesis under fluoroscopic guidance and local anaesthesia only.

Heart (British Cardiac Society) (2014-01-25)
Martin Greif, Philipp Lange, Michael Näbauer, Florian Schwarz, Christoph Becker, Christoph Schmitz, Tilmann Pohl, Melvin D'Anastasi, Peter Boekstegers, Steffen Massberg, Christian Kupatt
ABSTRAKT

To assess the feasibility of transcatheter aortic valve implantation (TAVI; Medtronic CoreValve and Edwards SAPIEN XT) under local anaesthesia with only mild analgesic medication and fluoroscopic guidance. 461 patients underwent TAVI under local anaesthesia with lidocaine. The procedure was performed successfully in 459 of the cases. All patients were also treated with piritramide, metoclopramide hydrochloride and 62 mg dimenhydrinate. Monitoring consisted of a six-electrode, virtual 12-lead ECG, pulse oximetry, and invasive arterial pressure measurement. There was no continuous surveillance by an anaesthesiologist. There was no need for conversion to general anaesthesia except in four patients who required cardiopulmonary resuscitation. Conscious sedation with intravenous administration of midazolam for agitation or inotropic medication for prolonged hypotension was necessary in only seven of the 461 patients. The combined safety end point according to the Valve Academic Research Consortium consensus document was reached in 12.6%. Our results show that TAVI performed under local anaesthesia with only mild analgesic medication and under fluoroscopic guidance is feasible, with good outcome comparable to published data.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Lidocaine hydrochloride monohydrate, solid
Sigma-Aldrich
Lidocaine, analytical standard
Sigma-Aldrich
Lidocaine, powder
Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Lidocaine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Lidocaine, European Pharmacopoeia (EP) Reference Standard
Supelco
Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
Lidocaine, United States Pharmacopeia (USP) Reference Standard
Lidocaine hydrochloride, European Pharmacopoeia (EP) Reference Standard